Table 2.

Clinical, functional, and treatment characteristics of patients with EPS and long-term PD controls

CharacteristicPatients with EPS (n=7)Controls (n=28)P Value
Men71711.00
PD duration, mo57.8±7.655.9±4.20.84
Age at PD start, yr47.5±3.656.9±3.40.09
Underlying nephropathy0.24
 GN4332
 Vascular nephropathy1421
 Chronic pyelonephritis021
 Genetic disease1421
 Other or undetermined294
Charlson comorbidity index4.9±1.04.6±0.40.85
Diabetes, n240.17
Residual diuresis, ml/d1083±1591021±1300.78
Body mass index, kg/m222.9±1.122.3±0.60.67
Medications
 ACE inhibitors and/or ARBs57630.78
 Statins43290.10
β-blockers29140.58
Baseline adequacy
 Peritoneal Kt/V1.51±0.221.46±0.070.84
 Residual Kt/V0.97±0.160.80±0.090.42
 Total Kt/V2.48±0.152.23±0.090.20
Baseline functional parameters
 Net UF, ml743±124648±570.54
 D/P creatinine, 4 h0.75±0.050.74±0.050.96
 Sodium sieving0.05±0.010.05±0.010.44
PD modality, % APD100680.11
Glucose and icodextrin exposure
 Mean annual glucose exposure, kg122±9110±70.20
 Mean annual icodextrin exposure, kg51±447±30.43
Peritonitis
 Patients with peritonitis71711.00
 No. of peritonitis per patient1.4±0.41.3±0.20.84
 Peritonitis rate, patient−1×year−10.36±0.110.30±0.050.66
 Patients with GNR peritonitis14430.12
  • Data are presented as the mean±SEM or percentage, unless otherwise indicated. ACE, angiotensin converting enzyme; ARB, angiotensin 2 receptor antagonist; D/P, dialysate-over-plasma; APD, automated peritoneal dialysis; GNR, Gram-negative rod.